Amyotrophic lateral sclerosis
), also known as motor neurone disease
) and Lou Gehrig's disease
, is a specific disease that causes the death
which control voluntary muscles
. Some also use the term motor neuron disease
for a group of conditions of which ALS is the most common. ALS is characterized by stiff muscles
, muscle twitching
, and gradually worsening weakness due to muscles decreasing in size
. This results in difficulty speaking
, and eventually breathing
The cause is not known in 90% to 95% of cases. About 5–10% of cases are inherited
from a person's parents. About half of these genetic cases are due to one of two specific gene
s. The diagnosis is based on a person's signs and symptoms with testing done to rule out other potential causes.
No cure for ALS is known. A medication called riluzole
may extend life by about two to three months. Non-invasive ventilation
may result in both improved quality and length of life. The disease usually starts around the age of 60 and in inherited cases around the age of 50. The average survival from onset to death is two to four years. About 10% survive longer than 10 years. Most die from respiratory failure. In much of the world, rates of ALS are unknown. In Europe and the United States the disease affects about two people per 100,000 per year.
Descriptions of the disease date back to at least 1824 by Charles Bell
. In 1869, the connection between the symptoms and the underlying neurological problems was first described by Jean-Martin Charcot
, who in 1874 began using the term amyotrophic lateral sclerosis
. It became well known in the United States in the 20th century when in 1939 it affected the baseball player Lou Gehrig
and later worldwide following the 1963 diagnosis of cosmologist Stephen Hawking
. In 2014, videos of the Ice Bucket Challenge
went viral on the internet and increased public awareness of the condition.
ALS is a motor neuron disease
, also spelled "motor neurone disease", which is a group of neurological disorder
s that selectively affect motor neuron
s, the cells that control voluntary muscles
of the body, including amyotrophic lateral sclerosis (ALS), primary lateral sclerosis
, progressive muscular atrophy
, progressive bulbar palsy
, pseudobulbar palsy
, and spinal muscular atrophy
ALS itself can be classified a few different ways: by how fast the disease progresses (slow vs fast progressors), by whether it is inherited or sporadic, and by where it starts. Most commonly (~70% of the time) the limbs are affected first. In this case, neurons in the brain ( upper motor neurons
) and in the spinal cord ( lower motor neurons
) are dying and this form is called "limb onset". In about 25% of cases, muscles in the face, mouth, and throat are affected first because motor neurons in the part of the brain stem called the medulla oblongata
(formerly called the "bulb") start to die first along with lower motor neurons. This form is called "bulbar onset". In about 5% of cases muscles in the trunk of the body are affected first. In all cases the disease spreads and affects other regions. The symptoms may also be limited to one spinal region.
Those with leg amyotrophic diplegia and brachial amyotrophic diplegia have a longer survival compared to classic onset ALS.
Signs and symptoms
The disorder causes muscle weakness and atrophy
throughout the body due to the degeneration of the upper
and lower motor neuron
s. Individuals affected by the disorder may ultimately lose the ability to initiate and control all voluntary movement, although bladder and bowel function and the muscles responsible for eye movement
are usually spared until the final stages of the disorder.
or behavioral dysfunction is present in 30-50% of individuals with ALS. Around half of people with ALS will experience mild changes in cognition and behavior, and 10–15% will show signs of frontotemporal dementia
. Repeating phrases or gestures
, apathy, and loss of inhibition
are frequently reported behavioral features of ALS. Language dysfunction
, executive dysfunction
, and troubles with social cognition
and verbal memory
are the most commonly reported cognitive symptoms in ALS; a meta-analysis found no relationship between dysfunction and disease severity. However, cognitive and behavioral dysfunctions have been found to correlate with reduced survival in people with ALS and increased caregiver burden; this may be due in part to deficits in social cognition. About half the people who have ALS experience emotional lability
, in which they cry or laugh for no reason.
and the autonomic nervous system
are generally unaffected, meaning the majority of people with ALS maintain hearing
, and taste
The start of ALS may be so subtle that the symptoms are overlooked. The earliest symptoms of ALS are muscle weakness or muscle atrophy. Other presenting symptoms include trouble swallowing or breathing, cramping, or stiffness of affected muscles; muscle weakness affecting an arm or a leg; or slurred and nasal speech. The parts of the body affected by early symptoms of ALS depend on which motor neurons in the body are damaged first.
In limb-onset ALS, people first experience awkwardness when walking or running or even tripping over or stumbling may be experienced and often this is marked by walking with a " dropped foot
" which drags gently on the ground. Or if arm-onset, difficulty with tasks requiring manual dexterity such as buttoning a shirt, writing, or turning a key in a lock may be experienced.
In bulbar-onset ALS, initial symptoms will mainly be of difficulty speaking clearly or swallowing. Speech may become slurred, nasal in character, or quieter. There may be difficulty in swallowing and loss of tongue mobility. A smaller proportion of people experience "respiratory-onset" ALS, where the intercostal muscle
s that support breathing are affected first.
Over time, people experience increasing difficulty moving, swallowing ( dysphagia
), and speaking or forming words ( dysarthria
). Symptoms of upper motor neuron involvement include tight and stiff muscles ( spasticity
) and exaggerated reflexes ( hyperreflexia
) including an overactive gag reflex. An abnormal reflex commonly called Babinski's sign
also indicates upper motor neuron damage. Symptoms of lower motor neuron degeneration include muscle weakness and atrophy, muscle cramps, and fleeting twitches of muscles that can be seen under the skin (fasciculations) although twitching is not a diagnostic symptom and more of a side effect so twitching would either occur after or accompany weakness and atrophy.
Although the order and rate of symptoms vary from person to person, the disease eventually spreads to unaffected regions and the affected regions become more affected. Most people eventually are not able to walk or use their hands and arms, lose the ability to speak and swallow food and their own saliva, and begin to lose the ability to cough and to breathe on their own.
The rate of progression can be measured using an outcome measure called the "ALS Functional Rating Scale Revised (ALSFRS-R)", a 12-item instrument administered as a clinical interview or self-reported questionnaire that produces a score between 48 (normal function) and 0 (severe disability); it is the most commonly used outcome measure in clinical trials and is used by doctors to track disease progression. Though the degree of variability is high and a small percentage of people have a much slower disorder, on average, people with ALS lose about 0.9 FRS points per month. A survey-based study amongst clinicians showed that they rated a 20% change in the slope of the ALSFRS-R as being clinically meaningful.
Disorder progression tends to be slower in people who are younger than 40 at onset, are mildly obese, have disorder restricted primarily to one limb, and those with primarily upper motor neuron symptoms. Conversely, progression is faster and prognosis poorer in people with bulbar-onset disorder, respiratory-onset disorder, and frontotemporal dementia.
The CX3CR1 allelic
variants have also been shown to have an effect on the disorder's progression and life expectancy.
Difficulty in chewing and swallowing makes eating very difficult and increases the risk of choking or of aspirating food into the lungs. In later stages of the disorder, aspiration pneumonia
can develop, and maintaining a healthy weight can become a significant problem that may require the insertion of a feeding tube. As the diaphragm and intercostal muscle
s of the rib cage
that support breathing weaken, measures of lung function
such as vital capacity
and inspiratory pressure diminish. In respiratory-onset ALS, this may occur before significant limb weakness is apparent. Most people with ALS die of respiratory failure or pneumonia
Although respiratory support can ease problems with breathing and prolong survival, it does not affect the progression of ALS. Most people with ALS die between two and four years after the diagnosis. Around half of people with ALS die within 30 months of their symptoms beginning, and about 20% of people with ALS live between 5 years and 10 years after symptoms begin. Guitarist Jason Becker
has lived since 1989 with the disorder, while cosmologist Stephen Hawking
has survived for more than 50 years through 2017, but they are considered unusual cases.
Most people with ALS die in their own home, with their breath failing
while they sleep; people rarely choke to death.
About 5–10% of cases are directly inherited from a person's parents. Overall, first-degree relative
s of an individual with ALS have a 1% risk of developing ALS.
A defect on chromosome 21
, which codes for superoxide dismutase
, is associated with about 20% of familial cases of ALS, or about 2% of ALS cases overall. This mutation is believed to be transmitted in an autosomal dominant
manner, and has over a hundred different forms of mutation. The most common ALS-causing mutation is a mutant SOD1
gene, seen in North America; this is characterized by an exceptionally rapid progression from onset to death. The most common mutation found in Scandinavian countries, D90A-SOD1, is more slowly progressive than typical ALS, and people with this form of the disorder survive for an average of 11 years.
In 2011, a genetic abnormality known as a hexanucleotide repeat was found in a region called C9orf72
, which is associated with ALS combined with frontotemporal dementia ALS-FTD, and accounts for some 6% of cases of ALS among white Europeans.
While moderate to severe traumatic brain injury
is a risk for ALS, it is unclear if mild traumatic brain injury increases rates.
In 1994 the National Institute for Occupational Safety and Health
(NIOSH) reported a nonsignificant increase in nervous system disorders due to four cases of ALS among National Football League
(NFL) players. It was unclear if this was due to chance or not. Another study from 2012 also found a possible increase in ALS in NFL football players. An older study did not find an increased risk among high school football players. A 2007 review found an increased risk among soccer players. ALS may also occur more often among the US military veterans however the reason is unknown. This may be due to head injury.
After the 2012 report was released, some NFL players involved in the legal settlement with the NFL complained that the NFL, which initially agreed to pay $765 million, was not doing enough to help players. The judge in the case concurred, and the NFL then agreed to pay an unlimited amount of damages for players found to have ALS, Parkinson's disease
, Alzheimer's disease
Where no family history of the disease is present – i.e., in around 90% of cases – no cause is known. Possible associations for which evidence is inconclusive include military service, and smoking. Studies on military history and ALS frequency are inconsistent, but suggest a positive correlation. Various factors that have been proposed include exposure to environmental toxins (evidenced by geographical deployment studies) as well as alcohol and tobacco use during military service.
Studies also have focused on the role of glutamate
in motor neuron degeneration. Glutamate is one of the neurotransmitters
in the brain. Scientists have found, compared with healthy people, people with ALS have higher levels of glutamate in their serum
and spinal fluid. Riluzole
, which targets glutamate transporters, is currently the only FDA-approved drug for treatment of ALS. It has only a modest effect on survival, however, suggesting that excess glutamate is not the sole cause of the disease.
Certain studies suggested a link between sporadic ALS, specifically in athletes, and a diet enriched with branched-chain amino acid
s, a common dietary supplement among athletes, which cause cell hyperexcitability resembling that usually observed in people with ALS. The proposed underlying mechanism is that cell hyperexcitability results in increased calcium absorption by the cell, and thus brings about cell death of neuronal cells, which have particularly low calcium buffering capabilities.
Some evidence supports the hypothesis that superoxide dismutase 1 (SOD1) protein misfolding propagates between molecules in a similar fashion to prion
s. Similarly, it has been proposed that incorporation of the cyanobacterial toxin β-methylamino-l-alanine ( BMAA
) leads to another prion
-like protein misfolding propagation.
Another very common factor associated with ALS is a lesion
to the motor system in areas such as the frontotemporal lobes. Lesions in these areas often show signs of early deficit, which can be used to predict the loss of motor function
and result in the spread of ALS. The mechanisms of ALS are present long before any signs or symptoms become apparent. Before any muscular atrophy becomes apparent during ALS, roughly one-third of the motor neurons
must be destroyed.
Other potential risk factors including chemical exposure, electromagnetic field exposure, occupation, physical trauma, and electric shock have been investigated but are without consistent findings. There is a tentative association with exposure to a number of pesticide
s including the organochlorine insecticide
, and toxaphene
The defining feature of ALS is the death of both upper
and lower motor neuron
s in the motor cortex
of the brain, the brain stem, and the spinal cord. Prior to their destruction, motor neurons develop protein-rich inclusions
in their cell bodies and axon
s. This may be partly due to defects in protein degradation. These inclusions often contain ubiquitin
, and generally incorporate one of the ALS-associated proteins: SOD1, TAR DNA binding protein
(TDP-43, or TARDBP), or FUS
. The mutant SOD1 may also contribute to motor neuron cell death through generating free radicals.
, or cell death caused by high levels of intracellular calcium caused by excessive activity of excitatory neurotransmitters, may be a mechanism of ALS. This concept has been supported by increased glutamate and dysfunctional glutamate transporter
in cerebrospinal fluid
of those with ALS. This is further supported by the only effective treatment being an anti-glutaminergic drug ( Riluzole
), as well as the poor ability to buffer calcium in motor neurons relative to other neurons.
Neurofilament accumulation in axons has been observed in sporadic cases of ALS as well as in SOD1 patients, possibly interfering with axonal transport
, leading to cell death from SOD1 toxicity.
) demonstrates increased T2
signal within the posterior part of the internal capsule
, consistent with the diagnosis of ALS.]]
No test can provide a definite diagnosis of ALS, although the presence of upper and lower motor neuron signs in a single limb is strongly suggestive. Instead, the diagnosis of ALS is primarily based on the symptoms and signs the physician
observes in the person and a series of tests to rule out other diseases. Physicians obtain the person's full medical history
and usually conduct a neurologic examination at regular intervals to assess whether symptoms such as muscle weakness, atrophy of muscles, hyperreflexia
, and spasticity are worsening.
Because symptoms of ALS can be similar to those of a wide variety of other, more treatable diseases or disorders, appropriate tests must be conducted to exclude the possibility of other conditions. One of these tests is electromyography
(EMG), a special recording technique that detects electrical activity in muscles. Certain EMG findings can support the diagnosis of ALS. Another common test measures nerve conduction velocity
(NCV). Specific abnormalities in the NCV results may suggest, for example, that the person has a form of peripheral neuropathy
(damage to peripheral nerves) or myopathy
(muscle disease) rather than ALS. While a magnetic resonance imaging
(MRI) is often normal in people with early stage ALS, it can reveal evidence of other problems that may be causing the symptoms, such as a spinal cord tumor, multiple sclerosis
, a hernia
ted disk in the neck, syringomyelia
, or cervical spondylosis
Based on the person's symptoms and findings from the examination and from these tests, the physician may order tests on blood and urine
samples to eliminate the possibility of other diseases, as well as routine laboratory tests. In some cases, for example, if a physician suspects the person may have a myopathy rather than ALS, a muscle biopsy may be performed.
Viral infectious disease
s such as human immunodeficiency virus ( HIV
), human T-cell leukemia virus ( HTLV
), Lyme disease
and tick-borne encephalitis
can in some cases cause ALS-like symptoms. Neurological disorders such as multiple sclerosis, post-polio syndrome
, multifocal motor neuropathy
, spinal muscular atrophy
, and spinal and bulbar muscular atrophy
can also mimic certain aspects of the disease and should be considered.
ALS must be differentiated from the "ALS mimic syndromes" which are unrelated disorders that may have a similar presentation and clinical features to ALS or its variants. Because of the prognosis carried by this diagnosis and the variety of diseases or disorders that can resemble ALS in the early stages of the disease, people with ALS symptoms should always obtain a specialist neurological opinion in order to rule out alternative diagnoses. Myasthenic syndrome
, also known as Lambert–Eaton syndrome, can mimic ALS, and its initial presentation can be similar to that of myasthenia gravis
(MG), a treatable autoimmune disease sometimes mistaken for ALS.
Benign fasciculation syndrome
is another condition that mimics some of the early symptoms of ALS but is accompanied by normal EMG readings and no major disablement.
Most cases of ALS, however, are correctly diagnosed, with the error rate of diagnosis in large ALS clinics is less than 10%. One study examined 190 people who met the MND/ALS diagnostic criteria, complemented with laboratory research in compliance with both research protocols and regular monitoring. Thirty of these people (16%) had their diagnosis completely changed during the clinical observation development period. In the same study, three people had a false negative diagnosis of MG, which can mimic ALS and other neurological disorders, leading to a delay in diagnosis and treatment. MG is eminently treatable; ALS is not.
Management of ALS attempts to relieve symptoms and extend life expectancy. This supportive care is best provided by multidisciplinary teams of healthcare professionals working with the person and their caregivers to keep them as mobile and comfortable as possible.
has been found to modestly prolong survival by approximately two to three months. It may have a greater survival benefit for those with a bulbar
onset. It is approved by the US Food and Drug Administration
(FDA) and recommended by the National Institute for Health and Care Excellence (NICE)
(England and Wales). Riluzole does not reverse damage already done to motor neurons but affects neurons by reducing their activity through blocking Na+ entrance into the neurons and thus blocking the release of the chemicals that causes the activity of the motor neurons. The reduction in activity prevents the ruining of the neuronal muscle and so the drug can act as a protective chemical. Studies have shown that the function of this drug is dependent on the amount taken at a given time. The higher the concentration, the better the drug will protect the neurons from ruin. The recommended dosage of Riluzole is 50 mg, twice a day for people with known ALS for more than 5 years.
There are a number of side effects caused by the drug including the feeling of weakness in muscles but this is normal due to the function of the drug. Studies have shown that people on the drug are not likely to stop responding to it or develop symptoms that might cause the activity of neurons to rise again, making Riluzole an effective drug for prolonging survival.
In 2015, edaravone
was approved in Japan for treatment of ALS after studying how and whether it works on 137 people with ALS and has obtained orphan drug
status in the EU and USA. On May 5, 2017, the FDA approved edaravone to extend the survival period of people with ALS. It costs about 145,000 USD per year in the US and 35,000 USD per year in Japan.
Other medications may be used to help reduce fatigue, ease muscle cramps, control spasticity, and reduce excess saliva and phlegm
. Drugs also are available to help people with pain, such as non-steroidal and anti-inflammatory drugs and opioids, depression, sleep disturbances, dysphagia, and constipation. Baclofen
are often prescribed to control the spasticity caused by ALS, and trihexyphenidyl
or most commonly glycopyrrolate may be prescribed when people with ALS begin having trouble swallowing their saliva. There is no evidence that medications are effective at reducing muscle cramps experienced by people with ALS.
Respiratory failure is the most common cause of death in people with ALS and is the most prominent symptom, second to the destruction of motor neurons and weakening of muscle. When the muscles that assist in breathing weaken,several symptoms start to arise including shortness of breath when undergoing physical activity or talking, fatigue, morning headaches, poor concentration and depression. The use of ventilatory assistance ( intermittent positive pressure ventilation
, bilevel positive airway pressure
(BiPAP), or biphasic cuirass ventilation
(BCV) may be used to aid breathing. Such devices artificially inflate the person's lungs from various external sources that are applied directly to the face or body. When muscles are no longer able to maintain oxygen and carbon dioxide levels, these devices may be used full-time. BCV has the added advantage of being able to assist in clearing secretions by using high-frequency oscillations followed by several positive expiratory breaths. People may eventually consider forms of mechanical ventilation (respirators) in which a machine inflates and deflates the lungs. To be effective, this may require a tube that passes from the nose or mouth to the windpipe ( trachea
) and for long-term use, an operation such as a tracheotomy
, in which a plastic breathing tube
is inserted directly in the person's windpipe through an opening in the neck.
Persons and their families should consider several factors when deciding whether and when to use one of these options. Ventilation devices differ in their effect on the person's quality of life and in cost. Although ventilation support can ease problems with breathing and prolong survival, it does not affect the progression of ALS. People need to be fully informed about these considerations and the long-term effects of life without movement before they make decisions about ventilation support and have deep discussions on quality of life. Some persons under long-term tracheostomy intermittent positive pressure ventilation with deflated cuffs or cuffless tracheostomy tubes (leak ventilation) are able to speak, provided their bulbar muscles are strong enough, though in all cases speech will be lost as the disease progresses. This technique preserves speech in some persons with long-term mechanical ventilation. Other persons may be able to use a speaking valve such as a Passey-Muir speaking valve with the assistance and guidance of a speech-language pathologist.
External ventilation machines that use the ventilation mode of BiPAP are frequently used to treat respiratory insufficiency at night, and later during the daytime. The use of BPAP (more often referred to as noninvasive ventilation, NIV) has shown to prolong survival and slow down the progression of forced vital capacity but long before BPAP stops being effective, persons should decide whether to have a tracheotomy
and long-term mechanical ventilation. At this point, some persons choose palliative hospice care
plays a large role in rehabilitation for individuals with ALS. Specifically, physical, occupational, and speech therapists can set goals and promote benefits for individuals with ALS by delaying loss of strength, maintaining endurance, limiting pain, improving speech and swallowing, preventing complications, and promoting functional independence.
Occupational therapy and special equipment such as assistive technology
can also enhance people's independence and safety throughout the course of ALS. Gentle, low-impact aerobic exercise
such as performing activities of daily living, walking, swimming, and stationary bicycling
can strengthen unaffected muscles, improve cardiovascular health, and help people fight fatigue and depression. Range of motion and stretching exercises can help prevent painful spasticity
and shortening (contracture) of muscles. Physical and occupational therapists can recommend exercises that provide these benefits without overworking muscles because muscle exhaustion can lead to worsening of symptoms associated with ALS rather than provide help to people with ALS. They can suggest devices such as ramps, braces, walkers, bathroom equipment (shower chairs, toilet risers, etc.), and wheelchairs that help people remain mobile. Occupational therapists can provide or recommend equipment and adaptations to enable ALS people to retain as much safety and independence in activities of daily living as possible.
People with ALS who have difficulty speaking may benefit from working with a speech-language pathologist
. These health professionals can teach people adaptive strategies such as techniques to help them speak louder and more clearly. As ALS progresses, speech-language pathologists can recommend the use of augmentative and alternative communication
such as voice amplifiers, speech-generating devices (or voice output communication devices) or low-tech communication techniques such as head mounted laser pointers, alphabet boards
or yes/no signals.
People with ALS and caregivers can learn from dieticians how to plan and prepare numerous small meals throughout the day that provide enough calories, fiber and fluid, and how to avoid foods that are difficult to swallow. Providing meals with vitamin E and taking vitamin E supplements have shown to slow down the progression of ALS. People may begin using suction devices to remove excess fluids or saliva and prevent choking. Occupational therapists can assist with recommendations for adaptive equipment to ease the physical task of self-feeding. Speech-language pathologists make food choice recommendations that are more conducive to their unique deficits and abilities. When people with ALS can no longer get enough nourishment from eating, doctors may advise inserting a feeding tube
into the stomach. The use of a feeding tube also reduces the risk of choking and pneumonia that can result from inhaling liquids into the lungs. The tube is not painful and does not prevent people from eating food orally if they wish.
Researchers have stated, "ALS patients have a chronically deficient intake of energy and recommended augmentation of energy intake" and have a severe loss of appetite. Both animal and human research suggest that ALS patients should be encouraged to consume as many calories as possible and not to restrict their caloric intake. As of 2012, "a lack of robust evidence for interventions" remained for the management of weight loss.
End of life care
ers and home care and hospice
nurses help people with ALS, their families, and caregivers with the medical, emotional, and financial challenges of coping, particularly during the final stages of the disease. Social workers provide support such as assistance in obtaining financial aid, arranging durable power of attorney
, preparing a living will
, and finding support groups for patients and caregivers. Home nurses are available not only to provide medical care, but also to teach caregivers about tasks such as maintaining respirators, giving feedings, and moving people to avoid painful skin problems and contractures. Home hospice nurses work in consultation with physicians to ensure proper medication, pain control, and other care affecting the quality of life of people with ALS who wish to remain at home. The home hospice team can also counsel people with ALS and caregivers about end-of-life issues.
In much of the world, rates of ALS are unknown. In Europe, the disease affects about 2.2 people per 100,000 per year. In the United States, more than 5,600 are diagnosed every year (over 1.87 per 100,000 per year), and up to 30,000 Americans are currently affected. ALS is responsible for two deaths per 100,000 people per year. ALS Association.
Quick Facts About ALS & The ALS Association.
ALS is classified as a rare disease, designated by the FDA as an “orphan” disease (affecting fewer than 200,000 people in the United States), but is the most common motor neuron disease. People of all races and ethnic backgrounds are affected. One or two of 100,000 people develop ALS each year. Amyotrophic lateral sclerosis affects around 30,000 Americans. ALS cases are estimated at 1.2–4.0 per 100,000 individuals in Caucasian populations with a lower rate in other ethnic populations. Filipinos
are second to Caucasians in terms of ALS prevalence with 1.1-2.8 per 100,000 individuals.
Reports have been made of several "clusters" including three American football
players from the San Francisco 49ers
, more than 50 association football
players in Italy, three association football-playing friends in the south of England, and conjugal (husband and wife) cases in the south of France. Although many authors consider ALS to be caused by a combination of genetic and environmental risk factors, so far the latter have not been firmly identified, other than a higher risk with increasing age.
Descriptions of the disease date back to at least 1824 by Charles Bell
English scientist Augustus Waller
described the appearance of shriveled nerve fibers in 1850. In 1869, the connection between the symptoms and the underlying neurological problems were first described by Jean-Martin Charcot
, who initially introduced the term amyotrophic lateral sclerosis
in his 1874 paper. In 1881, the article was translated into English and published in a three-volume edition of Lectures on the Diseases of the Nervous System
ALS became a cause célèbre
in the United States in 1939 when baseball legend Lou Gehrig
's career, and two years later, his life, were ended by the disease.
In the 1950s, an epidemic
occurred among the Chamorro people
which bore similarities to many conditions, including ALS.
By 1991, researchers had linked chromosome 21 to familial ALS (FALS). In 1993, the SOD1
gene on chromosome 21 was found to play a role in some cases of FALS. In 1996, riluzole became the first FDA-approved drug for ALS.
In 1998, the El Escorial criteria were developed as the standard for classifying people with ALS in clinical research. The next year, the revised ALS Functional Rating Scale was published and soon becomes a gold standard for clinical research. Noncoding repeat expansions in C9ORF72
were found to be a major cause of ALS and frontotemporal dementia in 2011.
Amyotrophic comes from the Greek
means "no", myo
refers to "muscle", and trophia
means "nourishment"; amyotrophia
therefore means "no muscle nourishment," which describes the characteristic atrophy
of the sufferer's disused muscle tissue. Lateral identifies the areas in a person's spinal cord where affected portions of the nerve cells are located. Degeneration in this area leads to scarring or hardening (" sclerosis
countries, the term "motor neurone disease" (MND) is commonly used.
Society and culture
In August 2014, a challenge went viral
online which was commonly known as the " ALS Ice Bucket Challenge
". Contestants fill a bucket full of ice and water, then state who nominated them to do the challenge, and nominate three other individuals of their choice to take part in it. The contestants then dump the buckets of ice and water onto themselves. However, it can be done in a different order. The contestants then donate at least US $
10 (or a similar amount in their local currency) to ALS research at the ALS Association
, the ALS Therapy Development Institute
, ALS Society of Canada
or Motor Neurone Disease Association
in the UK. Any contestants who refuse to have the ice and water dumped on them are expected to donate at least US$100 to ALS research. As of July 2015, the Ice Bucket Challenge had raised $115 million for the ALS Association. Many celebrities have taken part in the challenge. The Ice Bucket Challenge was credited with helping to raise funds that contributed to the discovery that the gene NEK1
may potentially contribute to the development for ALS.
ALS has been discussed and depicted late in the second season of Stargate Universe
science fiction series, particularly in episode "Epilogue (Part 2)", which first aired on 25 April 2011. Stargate Universe (season 2)
ALS is the central topic of the 2014 movie You're Not You
, directed by George C. Wolfe
, with Hilary Swank
, Emmy Rossum
and Josh Duhamel
playing the main characters.
, covered ALS in Season 4 Episode 16: Die Trying.https://als.vice.com/
Repetitive transcranial magnetic stimulation
had been studied in ALS in small and poorly designed clinical trials; as of 2013, there was insufficient evidence to know whether rTMS is safe or effective for ALS.
One 2016 review of stem cell therapy
trials found tentative evidence that intraspinal stem cell implantation was relatively safe and possibly effective. A 2016 Cochrane review
of cell based therapies found that there was insufficient evidence to speculate about efficacy. Stem cell therapy can provide additional proteins and enzymes that have shown to help prolong survival and control the symptoms associated with ALS. Those proteins include neurotrophic factors and insulin-like growth factor 1. Both those proteins are still under clinical trials and need to be further studied to evaluate their efficiency and associated side effects.
has been approved as an orphan medication
in Europe and the United States with studies ongoing as of 2016. Medications tested but without evidence for efficacy include lamotrigine
, Vitamin E
, various neurotrophic factors, which has shown promise in both in-vitro and in-vivo models of ALS but is yet to be effective in human models of ALS and creatine. Beta-adrenergic agonist
drugs have been proposed as a treatment for their effects on muscle growth and neuroprotection, but there is insufficient research in humans to determine their efficacy.
If you intend to add links to non-profit organizations, charities, or web pages that you think may be of interest to people with ALS, please ensure you have thoroughly read and understand , Wikipedia's policies on external links. Most links are *not* suitable for Wikipedia, even if they would be helpful to people with ALS.